Key result
Milrinone lacks direct evidence for improving important clinical outcomes in patients with cerebral vasospasm after subarachnoid hemorrhage, though it may reduce delayed cerebral ischemia.
Why the study?
Whether the use of milrinone in patients with cerebral vasospasm after subarachnoid hemorrhage improves important clinical outcomes was evaluated.
Does milrinone improve important clinical outcomes in patients with cerebral vasospasm after subarachnoid hemorrhage?
Does milrinone improve important clinical outcomes in patients with cerebral vasospasm after subarachnoid hemorrhage?
Answers are grounded in this paper and cite their sources.
There is currently no direct evidence that milrinone improves important clinical outcomes in patients with cerebral vasospasm following subarachnoid hemorrhage, despite potential for reducing vasospasm-related delayed cerebral ischemia.
No direct evidence for milrinone improving important clinical outcomes in patients with cerebral vasospasm after subarachnoid hemorrhage was identified. Existing studies suggest some potential in reducing vasospasm-related DCI, but more definitive research is required.
No takes yet. Share an insight, caveat, or question.
Tripdatabase (2026) studied this question. Milrinone lacks direct evidence for improving important clinical outcomes in patients with cerebral vasospasm after subarachnoid hemorrhage, though it may reduce delayed cerebral ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: